Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GGT1 | P19440 | 1/20 | 0.42 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CPB2 | Q96IY4 | 6/20 | 0.34 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.33 |
| ▸ | CPB1 | P15086 | 1/20 | 0.33 |
| ▸ | RRM1 | P23921 | 1/20 | 0.33 |
| ▸ | PAOX | Q6QHF9 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2434944 | 0.81 | GGT1 (0.38) | GGT1GABRR1CPB2CPB1 | |
| SCHEMBL28686249 | 0.79 | GGT1 (0.42) | GGT1GABRR1CPB2CPB1 | |
| SCHEMBL9450993 | 0.78 | GGT1 (0.36) | GGT1GABRR1CPB2CPB1 | |
| SCHEMBL13688891 | 0.78 | SMN1; SMN2 (0.42) | CA2DPP7 | |
| SCHEMBL3136912 | 0.78 | PTGS1 (0.41) | CA2ALDH1A1PTGS1 | |
| SCHEMBL10877449 | 0.78 | SMN1; SMN2 (0.46) | CA2DPP7 | |
| SCHEMBL2524548 | 0.78 | SMN1; SMN2 (0.46) | CA2DPP7 | |
| SCHEMBL1337928 | 0.78 | TDP1 (0.42) | CA2RRM1PTGS1 | |
| SCHEMBL2526531 | 0.78 | SMN1; SMN2 (0.46) | CA2DPP7 | |
| SCHEMBL2434941 | 0.77 | GGT1 (0.34) | GGT1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140194349-A1 | HIV Protease Inhibiting Compounds | ABBVIE INC. (US) | 2014-07-10 | — | — | US | disclosed |
| EP-2266971-A2 | Hiv protease inhibiting compounds | Abbott Laboratories (US) | 2010-12-29 | — | — | EP | disclosed |
| US-7834043-B2 | Prevent reproduct of aids virus | ABBOTT LABORATORIES (US) | 2010-11-16 | — | — | US | disclosed |
| EP-1697344-A2 | HIV PROTEASE INHIBITING COMPOUNDS | ABBOTT LABORATORIES (US) | 2006-09-06 | — | — | EP | disclosed |
| US-20050148623-A1 | Prevent reproduct of aids virus | ABBVIE INC. | 2005-07-07 | — | — | US | disclosed |
| WO-2005058841-A2 | HIV PROTEASE INHIBITING COMPOUNDS | ABBOTT LABORATORIES (US) | 2005-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050148623-A1 | Prevent reproduct of aids virus | SERPINB1, PRSS1, SERPINA3 | GGT1 502/4885GABRR1 2387/4885CA2 4400/4885 |
| US-20140194349-A1 | HIV Protease Inhibiting Compounds | SERPINB1, HPN, DNPEP | GGT1 205/4885GABRR1 2254/4885CA2 3870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.